SLC5A2 and hydrops fetalis: Notwithstanding the recent success of sodium-glucose transport protein 2 (SGLT2) inhibitors for HF, recent analyses indicate a steady decline in the number of new cardiovascular drugs under development between 1990 and 2012 (Hwang et al., 1990).